Velmanase alfa

Velmanase alfa is a medicine used to treat mucopolysaccharidosis type IVA (MPS IVA), a rare inherited disorder. It works by replacing an enzyme called N-acetylgalactosamine-6-sulfatase that is missing in people with MPS IVA. Velmanase alfa is given as an infusion into a vein (intravenous or IV infusion). It helps to reduce the buildup of glycosaminoglycans (GAGs) in the body, which can lead to organ and tissue damage.

Velmanase alfa, also known by the brand name Lampalizumab, is an enzyme replacement therapy used to treat a rare inherited metabolic disorder called mucopolysaccharidosis type 1 (MPS I) or Hurler-Scheie syndrome [1,2].

Here's a breakdown of how Velmanase alfa works:

• Genetic condition: MPS I is caused by a genetic mutation that results in a deficiency of the enzyme alpha-L-iduronidase. This enzyme is essential for breaking down complex sugars called glycosaminoglycans (GAGs) in the body.
• Enzyme replacement: Velmanase alfa acts as a replacement for the missing enzyme. It's a recombinant form of alpha-L-iduronidase produced in the lab to mimic the natural enzyme's function.
• Mechanism of action: By providing the enzyme, Velmanase alfa helps degrade accumulated GAGs in lysosomes (cellular compartments for waste disposal). This reduces the burden on cells and alleviates MPS I symptoms.

Administration:

• Intravenous infusion (IV drip): Typically administered once a week over a period of 60 minutes [2].

Important considerations:

• Chronic treatment: MPS I is a chronic condition, and Velmanase alfa is used for long-term management.
• Potential side effects: Infusion reactions, headache, fever, and chills are some reported side effects [2]. It's crucial to receive Velmanase alfa in a healthcare setting with proper medical supervision.
• Not a cure: While Velmanase alfa helps manage MPS I symptoms, it doesn't cure the underlying genetic condition.

Additional information:

• Developed by Shire plc [1].
• Received approval by the U.S. Food and Drug Administration (FDA) in 2014 for the treatment of MPS I in patients of all ages [2].